Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07620470
Recruiting Observational

Spectral Precise Image Study for Brain Tumors

NCT07620470 · tracked via the Priya Life Science China tracker
Sponsor
Philips Clinical & Medical Affairs Global
Phase
Observational
Started
2025-11-28
Last updated
2026-06-02

Condition(s) studied

Brain Tumors

Investigational drug(s) / intervention(s)

This is an observational data collection study

This is an observational data collection study: This is an observational data collection study

Study summary

The goal of this observational study is to explore the image quality of spectral CT deep learning reconstruction technology (Spectral Precise Image) of patients with confirmed brain tumors.

The main question it aims to answer is:

The Image Quality (IQ) and diagnostic confidence of Spectral Precise Image reconstructions

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: 1. Patients with clinical and radiology (MRI/CT) diagnosed brain tumors. 2. Patients who underwent contrast enhanced scans using the Spectral CT 7500. 3. Study participants with age ≥ 18 years old. 4. Study participants that have signed Informed Consent Form (ICF) Exclusion Criteria: 1. The clinical data or radiological information is considered incomplete after evaluation by the investigator. 2. Study participant that was enrolled in this study in the past 3. Data from study participants deemed unsuitable for enrollment based on the investigator's evaluation

Primary outcome measure(s)

  • Subjective Image quality using Likert score (1-5) — From date of image reconstruction until the date of image reading completion, anticipated 3Months.
    Image quality will be assessed by 2 radiologists using Likert score on a scale ranging from 1(poor) to 5(Excellent)
  • Objective Image Quality — From date of image reconstruction until the date of image reading completion, anticipated 3Months.
    The objective quality of the image is evaluated by measuring the CT value shown in the image.

Trial sites (1)

FacilityCityRegionStatus
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan Hubei Recruiting

More Philips Clinical & Medical Affairs Global trials in China

Clinical Study of Spectral CT Starting soon
Clinical Study of Spectral CT Verida Starting soon
Spectral Precise Image Study for Coronary Artery Starting soon
Spectral Precise Image-Colon Cancer Starting soon

Other trials for the same condition

Study of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid Tumors Starting soon
A Vision-Language Foundation Model for Brain Disease Diagnosis From Multimodal Data Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07620470 on ClinicalTrials.gov ↗ ← All trials in China